Shares of Cencora Inc. COR slid 2.82% to $246.13 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.36% to 6,083.57 and ...

James Cleary; Executive Vice President and Chief Financial Officer; Cencora Inc Thank you. Good morning, good afternoon, and thank you all for joining us for this conference call to discuss ...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global healthcare company, has significantly expanded the number and type of medications available in its sure supply program, a drug shortage ...

Cencora (COR) has significantly expanded the number and type of medications available in its sure supply program, a drug shortage mitigation initiative designed to provide health systems with ...

Hello, and welcome, everyone, to the Cencora Q1 fiscal year 2025 earnings call. My name is Becky, and I'll be your operator today. (Operator Instructions) I will now hand over to your host, Head of ...

Marks significant expansion of initiative to help health systems access critical, at-risk medications for patients Cencora, a global healthcare company, has significantly expanded the number and ...

Full Year Revenue Growth Guidance: 8% to 10%. Full Year Operating Income Growth Guidance: 11.5% to 13.5%. Cencora Inc (NYSE:COR) reported a strong start to fiscal year 2025 with a 13% increase in ...

Shares of Cencora, Inc. (NYSE:COR – Get Free Report) reached a new 52-week high on Wednesday after the company announced better than expected quarterly earnings. The company traded as high as $ ...

Cencora, a global healthcare company, has significantly expanded the number and type of medications available in its sure supply program, a drug shortage mitigation initiative designed to provide ...

COR's first-quarter fiscal 2025 results showcase a strong segmental performance. The company's sales and earnings guidance for fiscal 2025 looks encouraging.